Compare ZVIA & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZVIA | MXCT |
|---|---|---|
| Founded | 2007 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 193.4M | 160.0M |
| IPO Year | 2021 | 2021 |
| Metric | ZVIA | MXCT |
|---|---|---|
| Price | $1.85 | $1.47 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 4 |
| Target Price | $4.89 | ★ $7.50 |
| AVG Volume (30 Days) | ★ 1.2M | 682.2K |
| Earning Date | 02-25-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $162,849,000.00 | $34,419,000.00 |
| Revenue This Year | $7.60 | N/A |
| Revenue Next Year | $6.70 | $10.69 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.17 | N/A |
| 52 Week Low | $1.82 | $1.26 |
| 52 Week High | $4.99 | $5.20 |
| Indicator | ZVIA | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 25.10 | 42.00 |
| Support Level | $1.82 | $1.48 |
| Resistance Level | $1.96 | $1.59 |
| Average True Range (ATR) | 0.13 | 0.06 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 6.78 | 2.78 |
Zevia PBC is a beverage company disrupting the liquid refreshment beverage industry through refreshing, zero-calorie, zero-sugar, naturally sweetened beverages that are all Non-GMO Project Verified. It offers a platform of products that include a variety of flavors across Soda, Energy Drinks, Organic Tea, Mixers, Kidz drinks, and Sparkling Water. Its products are distributed across the U.S. and Canada through a network of retailers in the food, drug, mass, natural, and e-commerce channels. The company derives a majority of its revenue from the United States.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.